Table 1.
Patient baseline characteristics.
| Number | 149 |
| Female, n (%) | 88 (59) |
| Age, years | 60 ± 17 |
| Height, cm | 169 ± 10 |
| Weight, kg | 77 ± 17 |
| BMI, kg/m2 | 26.7 ± 5.2 |
| BSA, m2 | 1.9 ± 0.2 |
| Pulmonary hypertension classification (WHO) | |
| 1. Pulmonary arterial hypertension | 79 (53) |
| 1.1. Idiopathic | 31 (21) |
| 1.2. Hereditable | 1 (1) |
| 1.4.1. Connective tissue disease | 35 (23) |
| 1.4.2. HIV Infection | 3 (2) |
| 1.4.3. Portal hypertension | 3 (2) |
| 1.4.4. Congenital heart disease | 5 (3) |
| 1.4.5. Schistosomiasis | 1 (1) |
| 4.1. Chronic thromboembolic pulmonary hypertension | 70 (47) |
| Incident patients newly diagnosed not yet on therapy: PAH/CTEPH | 71 (90)/61 (87) |
| Pulmonary function tests, % predicted | |
| FEV1 | 84 ± 19 |
| FVC | 86 ± 18 |
| VC | 95 ± 20 |
| TLC | 95 ± 23 |
| DLCO | 62 ± 20 |
| Kco | 72 ± 20 |
Data are displayed as mean ± SD or as number (n) with percentage (%).
CTEPH, chronic thromboembolic pulmonary hypertension; DLCO, diffusion capacity of carbon monoxide; FEV1, forced expiration in the first second of expiration; FVC, forced vital capacity; KCO, carbon monoxide transfer coefficient; PAH, pulmonary arterial hypertension; TLC, total lung capacity; VC, vital capacity; WHO, World Health Organization; BMI, body mass index; BSA, body surface area.